Creso Pharma US Roadshow

ASX: CPH

OTC: COPHF FRA: 1X8

April 2022

Disclaimer

This presentation has been prepared by Creso Pharma Limited (Company or Creso). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents of this presentation, or any information provided in connection with it, as financial product advice or advice relating to legal, taxation or investment matters.

This presentation and the information contained herein and all electronic and/or hard copy documentation which comprise it are being provided to you solely for your information and may not be copied, reproduced, distributed, disclosed or published, in whole or in part, to any other person for any purpose whatsoever at any time without the prior written consent of Creso.

This presentation is not an offer to any person nor is it a prospectus.

Creso has prepared this document based on information available to it at the time of preparation. No representation or warranty (whether express or implied) is made by the Company or any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the information, statements, options or matters (express or implied) arising out of, contained in or derived from this presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability of any estimates, forecast or projections set out in this presentation.

This presentation is not investment or financial product advice (nor tax, accounting or legal advice) and is not intended to be used for the basis of making an investment decision. The information contained in this presentation has been prepared without taking into account the objectives, financial situation or needs of individuals.

This presentation is provided expressly on the basis that you will carry out your own independent inquiries into the matters contained in the presentation and make your own independent decisions about the affairs, financial position or prospects of the Company. The Company reserves the right to update, amend or supplement the information at any time in its absolute discretion (without incurring any obligation to do so).

To the maximum extent permitted by law, Creso, its related bodies corporate and the officers, directors, employees, advisers and agents of those entities do not accept any responsibility or liability including (but not limited to) any liability arising under the Australian Securities and Investments Commission Act 2001, Corporation Act 2001 or from the fault or negligence on the part of any person, for any loss arising from the use of the presentation or its contents arising in connection with it. Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell securities. It does not include all available information and should not be used in isolation as a basis to invest in the Company.

Future matters

This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of the Company.

Those intentions, expectations, future plans, strategy and prospectus may or may not be achieved. They are based on certain assumptions, which may not be met or on which views may differ and may be affected by known and unknown risks. The performance and operations of the Company may be influenced by a number of factors, many of which are outside the control of the Company. No representation or warranty, express or implied, is made by the Company, or any of its directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved either totally or partially or that any particular rate of return will be achieved.

Given the risks and uncertainties that may cause the Company's actual future results, performance or achievements to be materially different from those expected, planned or intended, recipient's should not place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company does not warrant or represent that the actual results, performance or achievements will be as expected, planned or intended.

US disclosure

This document does not constitute any part of any offer to sell, or the solicitation of any offer to buy, any securities in the United States or to, or for the account or benefit of any "US person" as defined in Regulation S under the US Securities Act of 1993 (Securities Act). The Company's shares have not been, and will be, registered under the Securities Act or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States or to any US person without being so registered or pursuant to an exemption from registration including any exemption for qualified institutional buyers.

2

Company overview

Business description

  • Founded in 2016 and ASX listed on 20 October 2016, trading under ASX code CPH

  • Revenue generating licensed cannabis producer in Canada with CBD R&D and marketing division in Switzerland

  • Only ASX-listed company with 100% ownership over a Canadian Licensed Producer and an established clinical psychedelic life sciences business

  • Innovative, Swiss-made hemp CBD product portfolio across four categories and global distribution agreements in place

  • Pending acquisition of Sierra Sage Herbs to provide access to US CBD market for Swiss product portfolio

  • Canopy Growth Co-Founder Bruce Linton (who grew Canopy to a peak market cap of C$28 billion) non-executive director of Creso board

Financial snapshot

Share Price 52-wk High 52-wk Low Shares on Issue Market Capitalisation Total Debt Outstanding Cash2

Enterprise Value

Source: S&P Capital IQ

  • 1 As at 31 Dec 2021

  • 2 As per FY21 Annual Report

Share performance vs cannabis indexOwnership structure1

1.296BnAUD

$0.072

$0.18

$0.05

$93.3m

Nil

$7.18m

0%

10%

20%

30%

40%

50%

$86.1m

Board & Management

60%

70%

80%

90%

100%

Top 20

Retail

3

Financial overview

FY2021 results overview - A$ mm unless otherwise noted

FY21 group revenue:

$6,218,337154%1

Mernova revenue:

$3,634,530199%1

Creso Swiss revenue:

$1,791,42685%1

Cash position:

$7,184,74619%2

  • 1 Compared to FY2020

  • 2 As at 31/12/2021

4

100% owned Canadian LP with indoor cannabis cultivation, rapidly scaling with high-quality premium product offeringDevelopment, production and global marketing of hemp derived products for human and animal health

US developer of beauty and personal care products, utilising proprietary plant based lipid infusion process, 110,000+ points of distribution in USCanadian clinical stage psychedelic drug development company Possesses dealer's licence from Health Canada

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Creso Pharma Ltd. published this content on 04 April 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 April 2022 23:47:03 UTC.